These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38383261)

  • 21. Long-term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical delta-aminolevulinic acid photodynamic therapy.
    Fink-Puches R; Soyer HP; Hofer A; Kerl H; Wolf P
    Arch Dermatol; 1998 Jul; 134(7):821-6. PubMed ID: 9681345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
    Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
    J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of basal cell carcinoma with intralesional interferon alfa-2b: an open-label clinical trial.
    Maleki M; Layegh P; Kiafar B; Teimoorian M; Darchini-Maragheh E; Razmara M
    Expert Rev Anticancer Ther; 2023 Jul; 23(7):753-760. PubMed ID: 37256542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2.
    Zagrodnik B; Kempf W; Seifert B; Müller B; Burg G; Urosevic M; Dummer R
    Cancer; 2003 Dec; 98(12):2708-14. PubMed ID: 14669293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and pathologic parameters predicting recurrence of facial basal cell carcinoma: a retrospective audit in an advanced care center.
    Troeltzsch M; Probst FA; Knösel T; Mast G; Ehrenfeld M; Otto S
    Int J Dermatol; 2016 Nov; 55(11):1281-1288. PubMed ID: 27420481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
    Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
    BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up.
    van Loo E; Mosterd K; Krekels GA; Roozeboom MH; Ostertag JU; Dirksen CD; Steijlen PM; Neumann HA; Nelemans PJ; Kelleners-Smeets NW
    Eur J Cancer; 2014 Nov; 50(17):3011-20. PubMed ID: 25262378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vismodegib for periocular and orbital basal cell carcinoma.
    Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
    JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma.
    Mohan SV; Chang J; Li S; Henry AS; Wood DJ; Chang AL
    JAMA Dermatol; 2016 May; 152(5):527-32. PubMed ID: 26914338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Basal cell carcinoma treated with interferon.
    Ikić D; Padovan I; Pipić N; Knezević M; Djaković N; Rode B; Kosutić I; Belicza M
    Int J Dermatol; 1991 Oct; 30(10):734-7. PubMed ID: 1955231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up.
    Schiessl C; Wolber C; Tauber M; Offner F; Strohal R
    J Drugs Dermatol; 2007 May; 6(5):507-13. PubMed ID: 17679185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Office-based treatment of basal cell carcinoma with immunocryosurgery: feasibility and efficacy.
    Nakuçi M; Bassukas ID
    Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):35-8. PubMed ID: 23836356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of basal cell carcinoma with intralesional interferon alpha: a case report and literature review.
    McDonald RR; Georgouras K
    Australas J Dermatol; 1992; 33(2):81-6. PubMed ID: 1294057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The recurrence of facial basal cell carcinoma in patients treated at the Head and Neck Surgery Ward and Laryngological Oncology Clinic of the Greater Poland Cancer Centre in the years 2007-2010].
    Pazdrowski J; Dańczak-Pazdrowska A; Golusiński P; Szybiak B; Silny W; Golusiński W
    Otolaryngol Pol; 2012; 66(3):185-90. PubMed ID: 22748679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of cutaneous tumors with topical 5% imiquimod cream.
    Alessi SS; Sanches JA; Oliveira WR; Messina MC; Pimentel ER; Festa Neto C
    Clinics (Sao Paulo); 2009; 64(10):961-6. PubMed ID: 19841702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intralesional interferon in basal cell carcinoma: how does it work?
    Buechner S; Wernli M; Bachmann F; Harr T; Erb P
    Recent Results Cancer Res; 2002; 160():246-50. PubMed ID: 12079220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mohs' micrographic surgery for treatment of basal cell carcinoma of the face--results of a retrospective study and review of the literature.
    Smeets NW; Kuijpers DI; Nelemans P; Ostertag JU; Verhaegh ME; Krekels GA; Neumann HA
    Br J Dermatol; 2004 Jul; 151(1):141-7. PubMed ID: 15270883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term recurrence rates of whole specimen intraoperative frozen section analysis in basal cell carcinomas of the face with WIFSA.
    Scholten LA; Kedilioglu MA; Huizinga PM; Kibbelaar RE; de Jong K; Mouës CM
    J Surg Oncol; 2019 Jun; 119(7):903-908. PubMed ID: 30737791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
    Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.